Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Hepatitis D Market Revenue Growth On Track For A 4.1% CAGR Through 2030
The hepatitis d market size has experienced consistent growth in recent years. It is projected to expand from $0.76 billion in 2025 to $0.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.4%. This historical progression can be ascribed to elements such as enhanced hepatitis B screening coverage, a heightened understanding of HDV severity, the broadening of diagnostic capabilities, an uptick in referrals to specialty centers, and the availability of targeted therapies.
The hepatitis d market is projected to experience consistent expansion over the upcoming years, reaching a valuation of $0.93 billion by 2030, progressing at a compound annual growth rate (CAGR) of 4.1%. This anticipated growth is driven by factors such as enhanced research efforts for new HDV treatments, a heightened emphasis on combination antiviral therapies, the broadening of prevention strategies tied to vaccination, increased understanding among high-risk demographics, and greater financial contributions to research on rare liver diseases. Key developments expected during this timeframe encompass a stronger emphasis on the early identification of co-infections, an uptick in the adoption of sophisticated serologic testing, an escalating need for bespoke treatment plans, the wider implementation of hospital-managed disease programs, and a sharpened focus on public understanding of the disease.
Get A Free Sample Report With In-Depth Market Insights:
Hepatitis D Market Expansion Drivers: What’s Shaping Future Growth?
A rising incidence of hepatitis B is anticipated to boost the expansion of the hepatitis D market in the future. Hepatitis B is a viral infection impacting the liver, manifesting with symptoms like jaundice, tiredness, and discomfort in the abdomen, and potentially progressing to chronic liver ailments or liver cancer if not addressed. The surge in Hepatitis B cases stems from factors including unprotected sexual activity, needle sharing, transmission from mother to child during birth, and inadequate vaccination rates in specific areas. Hepatitis D depends on the Hepatitis B virus for its reproduction, utilizing Hepatitis B’s surface antigen to infect liver cells; thus, co-infection by both viruses plays a crucial role in advancing liver disease. As an illustration, in April 2025, the Department of Health and Human Services, a US government entity, reported 17,650 newly identified chronic hepatitis B cases and 1,769 hepatitis B-related deaths in 2023. Consequently, the growing prevalence of hepatitis B is fueling the expansion of the hepatitis D market.
Hepatitis D Market Segment Outlook: Which Categories Are Growing Fastest?
The hepatitis d market covered in this report is segmented –
1) By Type: Acute, Chronic
2) By Diagnosis: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Other Diagnosis
3) By Distribution Channel: Hospital pharmacies, Retail pharmacies
4) By End-Users: Clinic, Hospital, Other End Users
Subsegments:
1) By Acute: Self-limiting Acute Hepatitis D, Severe Acute Hepatitis D
2) By Chronic: Compensated Chronic Hepatitis D, Decompensated Chronic Hepatitis D
Hepatitis D Market Industry Trends Fueling Future Revenue Growth
Key companies active in the hepatitis D market are prioritizing the development of innovative solutions, such as RNA-targeted antiviral therapy, to improve treatment outcomes and address outstanding medical needs in chronic hepatitis D infection. RNA-targeted antiviral therapy describes a treatment approach that directly targets a virus’s RNA to inhibit its replication, disrupt viral protein production, or silence viral genes, thereby lowering viral load and managing the infection. For example, in December 2024, Vir Biotechnology Inc., a US-based biotechnology firm, secured both the U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and the European Medicines Agency (EMA) Priority Medicines (PRIME) designation for its combination therapy involving tobevibart and elebsiran for treating chronic hepatitis delta (CHD).
Hepatitis D Market Leading Companies And Competitive Benchmarking
Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc., VBI Vaccines Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A., Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc., Bluejay Therapeutics Inc., Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc., Biorex Diagnostics Ltd.
View The Full Hepatitis D Market Report:
Hepatitis D Market Geographic Spread And Regional Opportunities
North America was the largest region in the hepatitis D market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









